Harbor Capital Advisors Inc. Decreases Position in Sarepta Therapeutics, Inc. (NASDAQ:SRPT)

Harbor Capital Advisors Inc. trimmed its position in shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPTFree Report) by 44.8% during the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 1,790 shares of the biotechnology company’s stock after selling 1,454 shares during the quarter. Harbor Capital Advisors Inc.’s holdings in Sarepta Therapeutics were worth $173,000 at the end of the most recent reporting period.

A number of other institutional investors also recently bought and sold shares of SRPT. DMC Group LLC lifted its position in shares of Sarepta Therapeutics by 2.9% in the third quarter. DMC Group LLC now owns 3,297 shares of the biotechnology company’s stock valued at $400,000 after acquiring an additional 93 shares in the last quarter. AQR Capital Management LLC grew its holdings in shares of Sarepta Therapeutics by 3.5% during the fourth quarter. AQR Capital Management LLC now owns 2,826 shares of the biotechnology company’s stock worth $366,000 after buying an additional 95 shares in the last quarter. D.A. Davidson & CO. grew its holdings in shares of Sarepta Therapeutics by 4.4% during the second quarter. D.A. Davidson & CO. now owns 2,383 shares of the biotechnology company’s stock worth $273,000 after buying an additional 100 shares in the last quarter. Acadian Asset Management LLC grew its holdings in shares of Sarepta Therapeutics by 11.2% during the first quarter. Acadian Asset Management LLC now owns 992 shares of the biotechnology company’s stock worth $136,000 after buying an additional 100 shares in the last quarter. Finally, Neuberger Berman Group LLC grew its holdings in shares of Sarepta Therapeutics by 2.5% during the third quarter. Neuberger Berman Group LLC now owns 4,250 shares of the biotechnology company’s stock worth $470,000 after buying an additional 105 shares in the last quarter. 91.82% of the stock is currently owned by hedge funds and other institutional investors.

Sarepta Therapeutics Price Performance

SRPT opened at $123.05 on Friday. The company has a 50 day moving average of $123.99 and a two-hundred day moving average of $109.60. Sarepta Therapeutics, Inc. has a 52-week low of $55.25 and a 52-week high of $159.89. The company has a quick ratio of 3.45, a current ratio of 3.95 and a debt-to-equity ratio of 1.32. The company has a market cap of $11.55 billion, a P/E ratio of -20.11 and a beta of 0.94.

Sarepta Therapeutics (NASDAQ:SRPTGet Free Report) last posted its earnings results on Wednesday, February 28th. The biotechnology company reported $0.47 EPS for the quarter, topping analysts’ consensus estimates of ($0.03) by $0.50. The business had revenue of $396.80 million for the quarter, compared to analysts’ expectations of $387.18 million. Sarepta Therapeutics had a negative net margin of 43.11% and a negative return on equity of 18.97%. The business’s revenue for the quarter was up 53.6% compared to the same quarter last year. During the same period in the previous year, the company posted ($1.24) earnings per share. On average, analysts expect that Sarepta Therapeutics, Inc. will post 1.85 earnings per share for the current year.

Insider Buying and Selling at Sarepta Therapeutics

In other news, insider Bilal Arif sold 2,000 shares of the firm’s stock in a transaction dated Friday, March 1st. The shares were sold at an average price of $128.84, for a total value of $257,680.00. Following the transaction, the insider now directly owns 26,836 shares in the company, valued at approximately $3,457,550.24. The transaction was disclosed in a legal filing with the SEC, which is available at this link. In other news, CFO Ian Michael Estepan sold 1,200 shares of the firm’s stock in a transaction dated Friday, March 1st. The shares were sold at an average price of $128.30, for a total value of $153,960.00. Following the transaction, the chief financial officer now directly owns 39,114 shares in the company, valued at approximately $5,018,326.20. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, insider Bilal Arif sold 2,000 shares of the firm’s stock in a transaction dated Friday, March 1st. The stock was sold at an average price of $128.84, for a total transaction of $257,680.00. Following the completion of the transaction, the insider now owns 26,836 shares in the company, valued at $3,457,550.24. The disclosure for this sale can be found here. Insiders have sold 22,096 shares of company stock worth $2,739,419 in the last ninety days. 7.40% of the stock is owned by insiders.

Wall Street Analyst Weigh In

A number of equities research analysts have recently commented on SRPT shares. Cantor Fitzgerald reiterated a “neutral” rating and set a $128.00 price target on shares of Sarepta Therapeutics in a report on Thursday, February 29th. Royal Bank of Canada lifted their price target on shares of Sarepta Therapeutics from $151.00 to $157.00 and gave the stock an “outperform” rating in a report on Thursday, February 29th. Citigroup lifted their price target on shares of Sarepta Therapeutics from $160.00 to $172.00 and gave the stock a “buy” rating in a report on Thursday, February 29th. Mizuho lifted their price target on shares of Sarepta Therapeutics from $130.00 to $145.00 and gave the stock a “buy” rating in a report on Wednesday, February 14th. Finally, UBS Group boosted their target price on shares of Sarepta Therapeutics from $164.00 to $167.00 and gave the company a “buy” rating in a report on Friday, March 1st. Five equities research analysts have rated the stock with a hold rating and thirteen have issued a buy rating to the company’s stock. Based on data from MarketBeat, Sarepta Therapeutics has a consensus rating of “Moderate Buy” and a consensus price target of $159.35.

View Our Latest Stock Report on Sarepta Therapeutics

Sarepta Therapeutics Company Profile

(Free Report)

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.

Read More

Institutional Ownership by Quarter for Sarepta Therapeutics (NASDAQ:SRPT)

Receive News & Ratings for Sarepta Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sarepta Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.